CIRM Clinical Trials
Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients.
CIRM funds clinical trials across a broad range of diseases and conditions that include rare and genetic disorders, treatment-resistant and refractory diseases, and many forms of cancer. Our involvement in the clinical trial process is vital to transforming potential treatments into available therapies by accelerating pathways to commercialization. Visit our Funding Opportunities page to apply for clinical trial research funding.
0
CIRM-Funded Clinical Trials
| Disease Areas | Investigator | Organization | Phase | Trial Status | Target Enrollment | Detail |
|---|---|---|---|---|---|---|
| Type 1 diabetes | Howard Foyt | ViaCyte, Inc. | Phase 1/2 | Closed | 19 | |
| Type 1 diabetes | Manasi Jaiman | ViaCyte, Inc. | Phase 1/2 | Completed | 49 | |
| Type 1 diabetes | Dr. William Sietsema | Caladrius Biosciences | Phase 2 | Completed | 113 | |
| Type 1 diabetes | Peter Stock | University of California, San Francisco | Phase 1/2 | Recruiting | 8 |
